Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tafolecimab Manufacturing Processes in Healthy Volunteers
NCT05792917Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of tafolecimab in hypercholesterolemia (2 arms), sponsored by Innovent Biologics. Primary endpoints: Peak Serum Drug Concentration at Day 57 and Area Under the Serum Concentration-Time Curve (0 to infinity) at Day 57. Started Mar 2023; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05792917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792917.